Navigation Links
Maine Company/Startup Undaunted by Bear Market
Date:10/8/2008

Continues with Plans to Revolutionize the Veterinary Pharmaceutical

Industry

PORTLAND, Maine, Oct. 8 /PRNewswire/ -- Putney, Inc., a pharmaceutical company focused on the development of generic drugs for pets, reports that the current Bear market will not hamper its plans to roll out a line of pet specific generic pharmaceuticals.

"Pet owners are committed to their pet's welfare and want the same standard of care for their pets as they expect for their children and other family members. Increased availability of generic veterinary medications will enhance the ability of pet owners, who pay out of pocket, to provide their pets with the health care they need," says Jean Hoffman, founder and CEO of Putney, Inc.

Hoffman's comment refers to two studies. Business Week recently reported that purchasing related to domestic companion animals, currently at $41B annually, is the second largest growing category of consumer spending. In a survey by Fleischman Hillard International Communications, fifty per cent of respondents say that a recession would not affect their pet spending. Putney's own focus groups have revealed that veterinarians are open to new generics; especially alternatives to pricey, chronic treatments.

Hoffman, an entrepreneur whose last enterprise, Newport Strategies, sold to Thomson Corporation in 2004, founded Putney to make pet healthcare more affordable and accessible -- a need she recognized when caring for her own aging cats. "Pets are cherished family members, yet many, including older pets that need medicines for chronic conditions, are not receiving the full dosage of their veterinarian prescribed medicines due to the high costs of pet pharmaceuticals," she says. Most human pharma products have a generic equivalent available when the patent expires, while 86% of companion animal drugs still have no generic equivalent available years beyond patent expiration.

Hoffman also cites the recently passed Animal Generic Drug User Fee Act as more cause for celebration. The law, which was passed in August, will cut FDA review time for proposed new generic drugs for pets from over 700 days to just 270 days -- greatly increasing Putney's ability to bring its products to market quickly.

Putney plans for its first FDA approved veterinary products to roll out in 2009, with more following in 2010 and 2011. By 2012, the company expects to have annual revenues more than $150M.

Putney, Inc. is a pharmaceutical company focused on the development of generic drugs for pets. The company's goal is to offer high quality prescribing options to veterinarians so price will cease to effect treatment options. The company has what it believes to be the deepest pipeline in animal health. Learn more at http://www.putneyvet.com.


'/>"/>
SOURCE Putney, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement from Dr. Charmaine Yoest, Americans United for Life, on Palin Daughters Pregnancy
2. Senator Susan Collins Praised for Leading Successful Effort to Derail $4.3 Million Maine Medicare Cuts
3. Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill
4. New Maine Economic Study: Bush Medicare Cuts Undermine State and Local Economic, Jobs Base
5. Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine
6. Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays
7. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
8. Anthem Sponsors Healthy Kids Day at Maines YMCAs
9. Toms of Maine Helps Increase Access to Dental Care
10. Toms of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes
11. Farm Bill Provision Will Disrupt MaineCare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
Breaking Medicine Technology: